BriefMD

Specialties / Rheumatology

New Rheumatology research.

The strongest recent Rheumatology papers on PubMed, ranked by study design, topic and journal, with the same summaries subscribers get.

  1. randomized trial, 58 patients

    Dual therapy with tofacitinib and steroids for acute severe ulcerative colitis: a randomized double-blind placebo-controlled trial

    Arora U, Verma M, Madan D, et al. J Crohns Colitis. Oct 2026.

    Findings
    In acute severe ulcerative colitis, unadjusted day 6 treatment failure was 24.2% with tofacitinib versus 36.0% with placebo (P = .33), but reached significance after baseline adjustment (adjusted RR 0.47; P = .03). Tofacitinib significantly lowered rescue therapy requirements over 90 days (HR 0.27; P = .01).
    Bottom line
    Adding tofacitinib to IV steroids reduced 90-day rescue therapy (HR 0.27) without significantly altering 90-day colectomy rates (12.1% vs 12.0%).

    PubMed, PMID 42909466

  2. meta-analysis, 11 studies

    Efficacy and safety of intravenous immunoglobulin in systemic sclerosis: a systematic review and meta-analysis

    de Carvalho JF, de Araujo RPC, Danieli MG, et al. Front Immunol. Jan 2026.

    Findings
    Eleven studies were included in the systematic review. Meta-analysis demonstrated a significant improvement in skin involvement assessed by the modified Rodnan Skin Score (SMD -0.59, 95% CI -0.95 to -0.22; p = 0.0019; I2 = 78.0%).
    Bottom line
    IVIG yields a modest skin benefit (SMD -0.59) and also improves gastrointestinal symptoms (SMD -0.73) and CK levels (SMD -0.53).

    PubMed, PMID 42898317

  3. phase iii trial, 36 patients

    Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase 3 BE MOBILE 1 Study

    Gu J, Lu L, Wang Q, et al. Rheumatol Ther. Oct 2026.

    Findings
    In 36 patients: A greater proportion of bimekizumab- vs placebo-randomised patients achieved ASAS ≥40% response (38.9% vs 22.2%).
    Bottom line
    Four serious adverse events and four fungal infections occurred among the Chinese cohort, representing 11.1% each, with most participants (32) completing the trial.

    PubMed, PMID 42920036

  4. meta-analysis, 4 studies

    Risk of myocardial infarction in adults with gout treated with allopurinol: A systematic review and meta-analysis

    Leon-Rodriguez JA, Agreda-Gil RL, Diaz-Rimarachin WS, et al. Diab Vasc Dis Res. Jan 2026.

    Findings
    Across four cohort studies, allopurinol use was associated with a reduced myocardial infarction risk (HR 0.84, 95% CI 0.76‑0.94).
    Bottom line
    Allopurinol therapy modestly lowers myocardial infarction risk in adults with gout.

    PubMed, PMID 42912780

  5. meta-analysis, 14 studies

    Association of rs3736228 polymorphism in LRP5 gene with bone fracture and osteoporosis: a systematic review and updated meta-analysis

    Zhang C, Liu W, Wang Y, et al. BMC Musculoskelet Disord. Jul 2026.

    Findings
    The current meta-analysis involved 14 studies, comprising 16 independent comparisons, including 1,549 patients and 3,345 control subjects. In the overall analysis, the polymorphism showed a higher likelihood of osteoporosis and fractures in the allelic model [OR=1.17, 95%CI(1.04-1.31), P=0.011].
    Bottom line
    The rs3736228 variant is associated with a 17% increased odds of osteoporosis or fracture (OR 1.17).

    PubMed, PMID 42907799

Summaries are written by AI from PubMed abstracts, for keeping up with the literature. Check the source before it changes care. Editorial policy · Medical disclaimer

Get Rheumatology research every morning.

Free. Choose your Rheumatology topics after you subscribe.